A multistakeholder approach to patient assistance programs was the topic of discussion at ACCC's first annual ICLIO meeting in Philadelphia.
Oncologists are increasingly aware of the hardships patients face as they choose newer oncolytic agents that promise better outcomes. The financial toxicity of healthcare, particularly in oncology, is not lost on anyone and drug companies have renewed their efforts with patient assistance programs, ensuring that physicians—in addition to patient support groups—are aware of the financial resources that patients can turn to. “We work extensively to provide clarity around our programs to clinicians,” shared Frank Marra, executive director, Patient Affordability and Executive Services at Bristol Myers Squibb.
Marra was part of a panel discussion at the first national meeting of the Institute for Clinical Immuno-Oncology, an initiative of the Association of Community Cancer Centers, held October 2, 2015, in Philadelphia. The panel followed a presentation by Linda House, RN, BSN, MSM, president, Cancer Support Community (CSC). According to House, the patients open up to CSC more than they do with their oncologists. “We try to work on psychosocial aspects of the patient’s care,” she said. In their 8000 cancer patient registry, CSC has observed that 75% of cancer patients follow their clinician’s advice when making health decisions. So with respect to newer, more expensive immuno-oncology agents, the quality of patient care is closely associated with reimbursement. And to be able to afford this expensive care, patients and their families sacrifice vacations, social events, and skimp on groceries, House said.
“Many live with chronic toxicities, and need follow-up care; 36% do not return to work.” Mental health conditions are an important side-effect associated with their suffering and “depression in cancer patients is estimated to cost about $8400 per patient,” said House, adding that the pharmaceutical industry is actively partnering with organizations like CSC to understand the needs of patients and to provide improved support. “We have 1-800 helplines at CSC, with mental health counselors on call,” and CSC’s partnership with Onyx Pharmaceuticals allows their support line to transfer callers to CSC’s helpline.
During the subsequent panel, Delali Attiogbe, site manager for BioOncology Managed Markets, Genentech, said that her company understands that patients do hold financial conversations with their treating physician and so her company is ensuring physician awareness on patient support programs. “We are also partnering with groups like CSC, arranging warm transfers of patients. There’s are dedicated groups within the company to help the process,” said Attiogbe.
Charles Lynch, program coordinator of Oncology Medical Assistance Program at Yale-New Haven Hospital, said “We have a support system at Yale that various health service providers are involved in, including clinicians, nurses, and social workers.” After the treatment clinic works out a treatment plan, his department calculates the patient’s out-of-pocket expenses and also evaluates the available alternatives on drug lists, Lynch explained. “We explore PAN [Patient Access Network] and PAF [Patient Advocate Foundation] foundation grants and copay cards…all the information is assessed to support care.”
When asked if the newer immuno-oncology agents have created unique challenges for patient assistance programs, Marra said that while similar challenges have persisted over the years, newer products have only amplified the problem. “We work extensively to provide clarity around our programs to clinicians and we are striving to enroll every patient in the program. Each patient is different and the program tries to adapt around their needs,” said Marra.
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More